Financials · QNRX

Quoin Pharmaceuticals Ltd. (QNRX) financials

For the twelve months ended Sep 30, 2026, Quoin Pharmaceuticals Ltd. reported -$19.59M of net income.

Net income, TTM
-$19.59M
Cash
$10.10M
Market cap
$17.1M
Annual revenue$0
FY2019FY2021
Annual net income-$15.80M
FY2017FY2025
Annual free cash flow-$1.44M
FY2017FY2020

QNRX revenue and earnings growth

QNRX net incomeQ3 2026-$4.87M

QNRX net income was -$4.87M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$3.95M a year earlier. For the full fiscal 2025 it was -$15.80M, compared with -$8.96M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2017
Revenue----$0$0$0-
Research and development$9.80M$3.60M$3.31M$2.67M$1.56M$244.2K$45.6K$3.32M
Selling, general and admin$6.49M$5.93M$6.07M$6.58M$4.50M$1.43M$1.51M$993.0K
Operating income------$4.35M-$6.46M-$7.05M
Interest expense----$1.09M$47.0K$425.0K$1.12M
Pre-tax income-$15.80M-$8.96M------
Net income-$15.80M-$8.96M-$8.69M-$9.38M-$21.46M-$2.10M-$1.56M-$8.14M
EPS, basic-----$0.01-$0.70-$0.52-
EPS, diluted-----$0.01-$0.70-$0.52-
Diluted shares----1.58B1.20B1.20B112.0M

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2017
Cash and equivalents$3.82M$3.62M$2.40M$2.86M$7.48M$323.8K$5.63M$3.96M
Short-term investments$14.93M$10.43M------
Receivables-----$5.0K$3.0K-
Current assets$20.01M$14.93M$11.29M$13.37M$8.20M$465.2K$5.38M$8.23M
Total assets$20.39M$15.71M$12.17M$14.46M$9.36M$1.38M$6.17M$8.76M
Current liabilities$5.55M$4.18M$3.58M$3.53M$4.58M$929.0K$1.05M$1.18M
Total liabilities$7.27M$6.50M$6.51M$7.05M$8.70M$7.99M$1.88M$3.32M
Shareholders' equity$13.12M$9.20M$5.66M$7.41M$657.0K-$6.61M-$4.51M$5.44M

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2017
Operating cash flow-$13.54M-$7.86M-$7.86M-$8.48M-$5.72M-$1.34M-$1.30M-$5.13M
Capital expenditures-----$103.0K$36.0K$77.0K
Free cash flow------$1.44M-$1.33M-$5.20M
Investing cash flow-$4.28M-$1.89M$2.19M-$10.15M-$625.0K-$125.0K-$31.0K$2.91M
Financing cash flow$18.01M$10.97M$5.22M$14.01M$13.50M$1.79M$1.30M$4.56M
Stock-based compensation$1.15M$1.26M$1.09M$764.0K-$229.0K$784.0K$1.55M
Depreciation and amortization-----$109.0K$108.0K$107.0K

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2017
Return on equity-120.5%-97.4%-153.4%-126.7%-3266.6%---149.7%
Return on assets-77.5%-57.1%-71.4%-64.9%-229.4%-152.1%-25.3%-92.9%
Current ratio3.613.573.153.791.790.505.116.97

Source: XBRL data Quoin Pharmaceuticals Ltd. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

QNRX peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
QNRX---$19.59M-$17.1M
KRYS$470.02M+26.0%$225.17M47.9%$8.83B
ABEO$39.01M+785.6%-$62.53M-160.3%$148.6M

QNRX FAQ

4 questions
  • Is QNRX profitable?
    No. Quoin Pharmaceuticals Ltd. reported a net loss of $19.59M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does QNRX have?
    Quoin Pharmaceuticals Ltd. reported $10.10M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • When did QNRX last report financial results?
    The latest statements here come from Quoin Pharmaceuticals Ltd.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.
  • Where does this QNRX financial data come from?
    Quantisnow builds these statements from the structured XBRL data Quoin Pharmaceuticals Ltd. files with the SEC. It is provided for information only and is not investment advice.